Perioperative Use of Erythromycin Reduces Cognitive Decline after Coronary Artery Bypass Grafting Surgery: A Pilot Study
Συγγραφέας
Thomaidou E., Argiriadou H., Vretzakis G., Megari K., Taskos N., Chatzigeorgiou G., Anastasiadis K.Ημερομηνία
2017Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Objectives Adverse neurologic outcome can be a debilitating complication after cardiac surgery. The aim of this study was to investigate the potential neuroprotective action of erythromycin, a well known antibiotic agent, regarding postoperative cognitive decline in patients undergoing cardiac surgery. Methods Forty patients scheduled for elective coronary artery bypass grafting surgery were prospectively randomly assigned in 2 groups: the erythromycin group (n = 19) who received erythromycin at a dose of 25 mg/kg before and after surgery and the control group (n = 21) who did not receive it. All patients were monitored with near-infrared spectroscopy during the operation. Interleukin (IL) 1 and IL-6 as inflammatory markers and tau protein as a marker of brain injury were measured before and after surgery. Neurocognitive assessment was performed before surgery, on the day of discharge, and at 3 months postoperatively. Results Both groups were comparable in terms of demographic and clinical data. Patients who took erythromycin presented with significantly better cognitive performance before discharge and 3 months after surgery. No significant differences between the 2 groups referring to IL-1 and IL-6 values were detected. Tau serum values were lower in the erythromycin group after surgery. Conclusions Erythromycin administration attenuates cerebral damage and postoperative cognitive decline after coronary artery bypass grafting surgery. Trial registration The study was retrospectively registered at ClinicalTrials.gov (NCT01274754). Study start day: November 2008. © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Collections
Related items
Showing items related by title, author, creator and subject.
-
IL-1 cytokines in cardiovascular disease: Diagnostic, prognostic and therapeutic implications
Apostolakis, S.; Vogiatzi, K.; Krambovitis, E.; Spandidos, D. A. (2008)Interleukins (ILs) are key mediators in the chronic vascular inflammatory response underlying several aspects of cardiovascular disease. Due to their powerful pro-inflammatory potential, and the fact that they are highly ... -
Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?
Vasileiadis G.K., Dardiotis E., Mavropoulos A., Tsouris Z., Tsimourtou V., Bogdanos D.P., Sakkas L.I., Hadjigeorgiou G.M. (2018)Current clinical experience with immunomodulatory agents and monoclonal antibodies in principle has established the benefit of depleting lymphocytic populations in relapsing–remitting multiple sclerosis (RRMS). B and T ... -
IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFNγ-producing T cells
Mavropoulos A., Varna A., Zafiriou E., Liaskos C., Alexiou I., Roussaki-Schulze A., Vlychou M., Katsiari C., Bogdanos D.P., Sakkas L.I. (2017)Our aim was to study CD19(+)CD27(+)CD24(high) memory and CD19(+)CD24(high)CD38(high) transitional and IL-10 + Breg cells, known to inhibit Th1 and Th17 cells in experimental arthritis, in psoriatic arthritis (PsA) and ...